小鼠抗SERPINB3單克隆抗體

Background:

Metastasis of a primary tumor to a distant site is determined through signaling cascades that break down interactions between the cell and extracellular matrix proteins. Among the proteins mediating metastasis are serine prote-ases, such as neutrophil elastase. In 1985, Dr. Jim Travis and Dr. R.W. Carrell designated an emerging family of serine protease inhibitors as the serpin fam-ily, which share homology in both primary amino acid sequence and tertiary structure. Serpins contain a stretch of peptide that mimics a true substrate for a corresponding serine protease. Serine proteases bind to this substrate mimic in a 1:1 stoichiometric fashion and become catalytically inactive. Aberrant ex-pression of serpin family members can contribute to a number of conditions, including emphysema (a-1 antitrypsin deficiency), fatal bleeding (elastase to thrombin specificity) and thrombosis (antithrombin deficiency), and are indicators of cancer stage phenotypes (circulating levels of squamous cell carcinoma antigen, known as SCCA1, increase in advancing stages of some cervical, lung, esophageal and head and neck cancers). Human chromosome position 18q21.3 contains a cluster of serpins, including a tandem duplication of the SCCA gene, plasminogen activator inhibitor type 2, and maspin. SCCA is transcribed by two nearly identical genes (SCCA1 and SCCA2), and is mainly produced as SCCA1. The human SCCA1 gene encodes a 390 amino acid protein that was originally isolated from a metastatic cervical squamous cell carcinoma.

Applications:

WB, IF

Name of antibody:

SERPINB3

Immunogen:

Fusion protein of human SERPINB3

Full name:

serpin peptidase inhibitor, clade B (ovalbumin), member 3 (SERPINB3)

Synonyms:

HsT1196; SCC; SCCA-1; SCCA-PD; SCCA1; T4-A

SwissProt:

P29508

WB Predicted band size:

45 kDa

WB Positive control:

COS7 cell lysate

WB Recommended dilution:

500-2000